Prevention of recurrent infection by fecal microbiota, live-jslm (REBYOTA) administered via colonoscopy: 6-month data from the single-arm phase IIIb CDI-SCOPE trial

Background: Fecal microbiota, live-jslm (RBL) is a microbiota-based product for the prevention of recurrent Clostridioides difficile infection (rCDI) in adults following antibiotic treatment. The safety and clinical effectiveness of RBL administered via colonoscopy in adults with rCDI were evaluated...

詳細記述

書誌詳細

主要な著者:	Sahil Khanna, David Yoho, Daniel Van Handel, Brian J. Clark, Tahany Awad, Beth Guthmueller, Daniel Armandi, Whitfield Knapple, Nasia Safdar, Brian Baggott, Karen Simon, Paul Feuerstadt
フォーマット:	Artigo
言語:	Inglês
出版事項:	SAGE Publishing 2025-11-01
シリーズ:	Therapeutic Advances in Gastroenterology
オンライン･アクセス:	https://doi.org/10.1177/17562848251396744
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!